Clinical trials: sponsored by Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Peripheral Arterial Disease
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes.
- Trial name
- STRIDE (NCT04560998)
- Testing
- Semaglutide
- Where
- 283 sites in United States, Austria and 19 more
- Volunteers
- 792 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes.
- Trial name
- NCT05813912
- Testing
- Insulin Icodec, Semaglutide
- Where
- 39 sites in Czechia, Malaysia and 3 more
- Volunteers
- 148 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight.
- Trial name
- STEP12 (NCT06041217)
- Testing
- Semaglutide
- Where
- 21 sites in China, Taiwan
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes.
- Trial name
- NCT05514535
- Testing
- Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
- Where
- 239 sites in United States, Czechia and 10 more
- Volunteers
- 573 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight.
- Trial name
- OASIS 1 (NCT05035095)
- Testing
- Oral semaglutide
- Where
- 56 sites in United States, Canada and 7 more
- Volunteers
- 667 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
The purpose of this research study is to compare the safety and effectiveness of 2 different doses of a study drug called ziltivekimab to placebo (an inactive substance) in reducing inflammation and improving some of the bad…
- Conditions
- Chronic Kidney Disease, Inflammation, Cardiovascular Risk
- Trial name
- RESCUE-2 (NCT04626505)
- Testing
- Ziltivekimab
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
This study looks at how a person with type 2 diabetes can be treated with insulin icodec and a flash glucose monitor (a small sensor inserted under the skin to measure blood sugar all the time).
- Trial name
- ONWARDS 9 (NCT05823948)
- Testing
- Insulin Icodec
- Where
- 20 sites in United States
- Volunteers
- 51 people
- Sponsor
- Novo Nordisk A/S
Obesity, Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study.
- Trial name
- NCT05649137
- Testing
- Semaglutide
- Where
- 76 sites in United States, Bulgaria and 6 more
- Volunteers
- 512 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in…
- Trial name
- STEP UP (NCT05646706)
- Testing
- Semaglutide
- Where
- 107 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,407 people
- Sponsor
- Novo Nordisk A/S
Primary Hyperoxaluria, Primary Hyperoxaluria Type 1
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
- Conditions
- Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
- Trial name
- PHYOX8 (NCT05001269)
- Testing
- nedosiran
- Where
- 13 sites in United States, Canada and 9 more
- Volunteers
- 27 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Diabetes Mellitus, Type 2
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.
- Trial name
- NCT05144984
- Testing
- NNC0480-0389, Semaglutide
- Where
- 129 sites in United States, Bulgaria and 7 more
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Alpha 1-Antitrypsin Deficiency
A Study of Belcesiran in Patients With AATLD
This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD).
- Trial name
- ESTRELLA (NCT04764448)
- Testing
- Belcesiran
- Where
- 23 sites in United States, Australia and 12 more
- Volunteers
- 16 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Type 2 Diabetes
The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.
The goal of this clinical trial is to compare the effect of a continuous glucose monitor (CGM) based titration algorithm to standard titration by self-monitoring blood glucose (SMBG) in participants with Type 2 Diabetes already…
- Trial name
- CGM-DTx (NCT06111508)
- Testing
- Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Virginia
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily.
- Trial name
- OASIS 4 (NCT05564117)
- Testing
- Semaglutide
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
- Trial name
- REMODEL (NCT04865770)
- Testing
- Semaglutide
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 106 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- STEP7 (NCT04251156)
- Testing
- Semaglutide
- Where
- 33 sites in Brazil, China and 2 more
- Volunteers
- 375 people
- Sponsor
- Novo Nordisk A/S
Obesity
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar…
- Trial name
- STEP 10 (NCT05040971)
- Testing
- Semaglutide 2.4 mg
- Where
- 43 sites in Canada, Denmark and 3 more
- Volunteers
- 207 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment…
- Trial name
- NCT02616562
- Testing
- somapacitan, Norditropin® FlexPro® pen
- Where
- 89 sites in United States, Austria and 12 more
- Volunteers
- 76 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.
- Trial name
- NCT05579249
- Testing
- Semaglutide, Orlistat, Phentermine/Topiramate
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S